- Home
- GERN vs PFLT Comparison
GERN vs PFLT Comparison
Compare GERN & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- PFLT
- Stock Information
- Founded
- GERN 1990
- PFLT 2010
- Country
- GERN United States
- PFLT United States
- Employees
- GERN N/A
- PFLT N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- PFLT Finance: Consumer Services
- Sector
- GERN Health Care
- PFLT Finance
- Exchange
- GERN Nasdaq
- PFLT Nasdaq
- Market Cap
- GERN 840.7M
- PFLT 808.2M
- IPO Year
- GERN 1996
- PFLT N/A
- Fundamental
- Price
- GERN $1.18
- PFLT $10.08
- Analyst Decision
- GERN Buy
- PFLT Buy
- Analyst Count
- GERN 9
- PFLT 4
- Target Price
- GERN $5.13
- PFLT $11.38
- AVG Volume (30 Days)
- GERN 11.5M
- PFLT 912.4K
- Earning Date
- GERN 05-07-2025
- PFLT 05-12-2025
- Dividend Yield
- GERN N/A
- PFLT 12.20%
- EPS Growth
- GERN N/A
- PFLT 16.92
- EPS
- GERN N/A
- PFLT 1.37
- Revenue
- GERN $116,293,000.00
- PFLT $215,391,000.00
- Revenue This Year
- GERN $194.54
- PFLT $48.14
- Revenue Next Year
- GERN $56.51
- PFLT $9.03
- P/E Ratio
- GERN N/A
- PFLT $7.37
- Revenue Growth
- GERN 22264.04
- PFLT 47.56
- 52 Week Low
- GERN $1.17
- PFLT $8.82
- 52 Week High
- GERN $5.34
- PFLT $12.02
- Technical
- Relative Strength Index (RSI)
- GERN 32.46
- PFLT 48.36
- Support Level
- GERN $1.34
- PFLT $9.98
- Resistance Level
- GERN $1.44
- PFLT $10.18
- Average True Range (ATR)
- GERN 0.10
- PFLT 0.17
- MACD
- GERN 0.00
- PFLT 0.06
- Stochastic Oscillator
- GERN 3.23
- PFLT 79.49
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.